APA (7th ed.) Citation

Dituri, F., Scialpi, R., Schmidt, T. A., Frusciante, M., Mancarella, S., Lupo, L. G., . . . Giannelli, G. (2020). Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro. Cell death & disease, 11(11), 984. https://doi.org/10.1038/s41419-020-03180-8

Chicago Style (17th ed.) Citation

Dituri, Francesco, Rosanna Scialpi, Tannin A. Schmidt, Martina Frusciante, Serena Mancarella, Luigi Giovanni Lupo, Erica Villa, and Gianluigi Giannelli. "Proteoglycan-4 Is Correlated with Longer Survival in HCC Patients and Enhances Sorafenib and Regorafenib Effectiveness via CD44 in Vitro." Cell Death & Disease 11, no. 11 (2020): 984. https://doi.org/10.1038/s41419-020-03180-8.

MLA (9th ed.) Citation

Dituri, Francesco, et al. "Proteoglycan-4 Is Correlated with Longer Survival in HCC Patients and Enhances Sorafenib and Regorafenib Effectiveness via CD44 in Vitro." Cell Death & Disease, vol. 11, no. 11, 2020, p. 984, https://doi.org/10.1038/s41419-020-03180-8.